Pidnarulex
Phase 1Small molecule
Pidnarulex is one of 38 small molecule programs targeting Metastatic Malignant Solid Neoplasm. It is currently in Phase 1.
4
Indications
5
Total Trials
4
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Anatomic Stage III Breast Cancer AJCC V8
#DrugCompanyPhaseTrials
1Aromasin
PfizerPhase 3
Xentuzumab
SSyndax Pharmaceuticals
Phase 3
Zoladex
TTerSera Therapeutics LLC
Phase 3
Zoladex
TTerSera Therapeutics LLC
Phase 3
Talzenna
PfizerPhase 2
Tecentriq
RochePhase 2
Lynparza
AstraZenecaPhase 2
Keytruda
Merck & Co.Phase 1
Verzenio
Eli LillyPhase 1
Abraxane
Bristol-Myers SquibbPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer1 trial
Metastatic Malignant Solid Neoplasm1 trial
Metastatic Colorectal Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pidnarulex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)